Jehonathan H Pinthus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/947891/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease. Journal of Urology, 2019, 202, 1199-1208.	0.4	98
2	The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 183-191.	1.6	63
3	GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model1Contributed equally and share first authorship Urologic Oncology: Seminars and Original Investigations. 2014. 32. 1126-1134.	1.6	60
4	Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications. Canadian Urological Association Journal, 2011, 5, 274-282.	0.6	57
5	Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles. European Journal of Cancer, 2017, 70, 62-74.	2.8	48
6	Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer. Cancer Research, 2016, 76, 1603-1614.	0.9	40
7	An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis. International Journal of Molecular Sciences, 2017, 18, 470.	4.1	37
8	Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. Journal of Urology, 2016, 196, 1627-1633.	0.4	36
9	Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 464-475.	1.6	32
10	Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. British Journal of Anaesthesia, 2021, 126, 163-171.	3.4	29
11	Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 975-980.	1.6	26
12	Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology. BJU International, 2012, 110, 1142-1148.	2.5	24
13	Androgenâ€dependent regulation of medium and long chain fatty acids uptake in prostate cancer. Prostate, 2007, 67, 1330-1338.	2.3	23
14	Autoantibodies against the cell surface–associated chaperone GRP78 stimulate tumor growth via tissue factor. Journal of Biological Chemistry, 2017, 292, 21180-21192.	3.4	17
15	Clinical significance of the Lacdi NA câ€glycosylated prostateâ€specific antigen assay for prostate cancer detection. Cancer Science, 2019, 110, 2573-2589.	3.9	17
16	Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation. Oncology Reports, 2015, 34, 1968-1976.	2.6	15
17	Elevated Câ€Peptides, Abdominal Obesity, and Abnormal Adipokine Profile are Associated With Higher Gleason Scores in Prostate Cancer. Prostate, 2017, 77, 211-221.	2.3	13
18	Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study. Canadian Urological Association Journal, 2020, 15, 181-186.	0.6	13

#	Article	IF	CITATIONS
19	Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist. Prostate Cancer and Prostatic Diseases, 2021, 24, 177-185.	3.9	11
20	The relative contribution of urine extravasation to elevation of plasma creatinine levels in acute unilateral ureteral obstruction. Canadian Urological Association Journal, 2015, 9, 428.	0.6	9
21	Cardiovascular effects of androgen depletion and replacement therapy. Urology, 2006, 67, 1126-1132.	1.0	8
22	The contemporary role of lymph node dissection in the management of renal cell carcinoma. Therapeutic Advances in Urology, 2018, 10, 335-342.	2.0	8
23	Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. British Journal of Anaesthesia, 2021, 126, 172-180.	3.4	8
24	Characteristics of α2,3â€sialyl N â€glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level. Prostate, 2021, 81, 1411-1427.	2.3	8
25	Endoplasmic Reticulum Protein ERp46 in Renal Cell Carcinoma. PLoS ONE, 2014, 9, e90389.	2.5	7
26	Endoplasmic reticulum protein ERp46 in prostate adenocarcinoma. Oncology Letters, 2017, 13, 3624-3630.	1.8	6
27	Cancer prevention and screening in a BRCA2-positive male to female transgender patient. Breast Journal, 2018, 24, 1112-1113.	1.0	4
28	Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2019, 14, 122-129.	0.6	3
29	Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoEâ^'/â^':Ins2+/Akita mouse model. Prostate Cancer and Prostatic Diseases, 2021, 24, 389-397.	3.9	3
30	Uncovering the Metabolic Complications of Androgen Deprivation Therapy in Patients with Prostate Cancer—Where Do We Take it Next?. Journal of Urology, 2015, 193, 1882-1883.	0.4	2
31	Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy. Current Developments in Nutrition, 2021, 5, nzab106.	0.3	2
32	Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-NaÃ ⁻ ve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy. Journal of Urology, 2022, , 101097JU000000000002384.	0.4	2
33	The question of repeat biopsies. Canadian Urological Association Journal, 2012, 1, 250.	0.6	0
34	Does androgen-deprivation therapy for prostate cancer increase the risk for thromboembolic disease?. Canadian Urological Association Journal, 2017, 11, 39.	0.6	0
35	Editorial Comment. Journal of Urology, 2018, 200, 580-580.	0.4	0
36	Editorial Comment. Journal of Urology, 2021, 206, 621-622.	0.4	0

#	Article	IF	CITATIONS
37	Reply By Authors. Journal of Urology, 2019, 202, 1208-1208.	0.4	0
38	Prostate sparing radical cystectomy-not for all, but an option for some. Canadian Journal of Urology, 2006, 13 Suppl 1, 81-7.	0.0	0
39	The Cardiologist's Role in the Management of Patients with a Genitourinary Cancer Israel Medical Association Journal, 2022, 24, 175-178.	0.1	Ο